Creatd Forms Strategic Partnership with VTAK for Fly Flyte

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 17 2026

0mins

VTAK+25.55%

Should l Buy VTAK?

Source: Newsfilter

Investor Network Expansion: Creatd has successfully introduced a 20% equity investment in its subsidiary Fly Flyte through a partnership with NYSE-listed VTAK, enhancing Fly Flyte's capital base and providing financial support for future growth.
Portfolio Strategy Advancement: Creatd is actively engaged in multiple acquisition discussions, aiming to build a service foundation that supports growth-driven small-cap companies by integrating capabilities from banking, investing, and advisory services, thereby enhancing its market competitiveness.
Aviation Innovation Transformation: Fly Flyte leverages AI technology to provide regional aviation services designed to increase accessibility and convenience, creating real-time revenue through established routes and scalable infrastructure while positioning for long-term expansion.
Operational Independence Assurance: This investment not only provides financial backing for Fly Flyte but also ensures its operational independence and strategic focus, aligning with Creatd's emphasis on the long-term value creation potential of technology-enabled subsidiaries.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy VTAK?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on VTAK

About VTAK

Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Catheter Precision Completes 80% Acquisition of Flyte

8 hours agostocktwits

Acquisition Completed: Catheter Precision completed its acquisition of an 80% stake in Flyte on Tuesday, significantly increasing its market share in the rapidly growing private aviation sector, which led to a 50% surge in its stock price.
Capital Inflow: As part of the transaction, Creatd will receive approximately $6 million in cash and $6 million in convertible preferred stock, making it a significant shareholder in VTAK and laying the groundwork for future collaboration.
Financing Plan: Earlier this month, Catheter Precision signed a securities purchase agreement to raise about $1.9 million through a private placement, with proceeds aimed at working capital, restructuring, and reducing expenses, indicating proactive financial management.
Market Reaction: Following the acquisition announcement, retail sentiment for VTAK on Stocktwits flipped from 'bearish' to 'extremely bullish', with investors anticipating a price increase to $3, reflecting strong market confidence in the company's future prospects.

Creatd Sells Remaining Stake in Fly Flyte to Strengthen Financial Position

11 hours agoseekingalpha

Equity Sale Transaction: Creatd sold its remaining 80% stake in subsidiary Fly Flyte to Catheter Precision for approximately $6 million in cash and nearly $6 million in convertible preferred stock, significantly strengthening its financial position.
Strategic Shareholder Status: This transaction not only improves Creatd's balance sheet but also positions it as a significant shareholder in Catheter Precision, further solidifying its investment strategy in the medical technology sector.
Operational Optimization Background: Creatd implemented various operational and technological changes within a year of acquiring Fly Flyte, adequately preparing for this acquisition and demonstrating its capability in business integration and value enhancement.
Ongoing Collaborative Relationship: Despite the equity transfer, Creatd and Catheter Precision will continue to collaborate through a strategic relationship focused on aviation and eVTOL logistics platform development, ensuring synergistic effects in future business growth.

Catheter Precision Showcases LockeT Device at International Symposium

4 days agoNewsfilter

Conference Highlight: Catheter Precision's LockeT suture retention device will be showcased during live procedural cases at the 2026 International Symposium on Left Atrial Appendage, held from March 5-6 at the Biltmore Hotel in Los Angeles, featuring leading experts in cardiac electrophysiology.
Educational Opportunity: The symposium offers a unique chance for electrophysiology fellows to engage in hands-on demonstrations and product education, with Catheter Precision allowing fellows to experience LockeT firsthand and learn about its potential benefits, including cost reduction for hospitals and same-day discharge.
Industry Recognition: CEO David Jenkins noted that LockeT continues to gain traction at prestigious industry events, with its recent feature at the Structural Heart Intervention and Imaging conference underscoring its efficiency and cost-effectiveness in real-world clinical settings.
Technological Innovation: LockeT is a Class 1 medical device designed to assist in wound closure after percutaneous venous punctures, having received FDA registration and CE Mark approval, reflecting Catheter Precision's ongoing innovation and advancements in cardiac electrophysiology procedures.

Catheter Precision Divests Non-Core Assets to Focus on Electrophysiology

Feb 19 2026Benzinga

Strategic Divestiture: Catheter Precision announced the sale of its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer, aiming to enhance capital efficiency and focus on its high-growth electrophysiology platform.
Transaction Highlights: The deal includes a $15,000 upfront cash payment, a 5% equity stake in the acquiring company, and a ten-year royalty agreement on net sales, which is expected to accelerate execution across its electrophysiology product portfolio.
Stock Price Trend: VTAK shares are currently priced at $1.61, trading 21.1% below the 20-day simple moving average and 31.7% below the 100-day SMA, indicating a bearish short-term trend.
Market Performance: Over the past 12 months, VTAK shares have decreased by 75.82%, nearing their 52-week low of $1.13, with a current RSI of 44.39 indicating neutral territory, while the MACD at -0.1249 suggests ongoing bearish pressure.